TGFB1 and thyroid gland carcinoma: Our data indicate that Apigenin may overcome RAIU reduction by TGF-β at the invasive fronts of thyroid cancer, in particular when Apigenin is administered in combination with PI3Ki, MEKi, or Hsp90i to further increase RAIU.